{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:05:13Z","timestamp":1785888313601,"version":"3.56.0"},"reference-count":26,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The prognosis of unresectable cutaneous squamous cell carcinomas is very poor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy and safety of panitumumab alone or in association with radiotherapy in the treatment of unresectable cutaneous squamous cell carcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a monocentre retrospective study of all consecutive patients having received at least two courses of panitumumab, alone or in association with radiotherapy, between 2016 and 2019. The primary endpoint was the rate of best overall response, evaluated according to the RECIST 1.1 criteria. The secondary endpoints were the response and disease control rates at 6\u00a0weeks and 6\u00a0months, progression\u2010free survival, overall survival and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 25 patients were included; their median age was 86\u00a0years, and 17 (86%) had a WHO performance status over 2. The best overall response rate was 52%, including four complete responses (16%) and nine partial responses (36%). All patients with complete response and five out of nine patients with partial response had received concurrent radiotherapy, in most cases in moderate to low doses (&lt;40 Gray, 67%). The response rates at 6\u00a0weeks and 6\u00a0months were 12% and 28%, respectively. The control rates at 6\u00a0weeks and 6\u00a0months were 84% and 32%, respectively. Median progression\u2010free survival was 6.9\u00a0months, and median overall survival was 10.5\u00a0months. Grade 3 side\u2010effects, mostly dermatological, occurred in 16 patients (64%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results suggest that panitumumab remains pertinent in the treatment of unresectable cutaneous squamous cell carcinoma, in particular in association with radiotherapy, despite recent advances with anti\u2010PD\u20101 antibodies. It presents several advantages: it can be used in very elderly or feeble patients, it does not provoke anaphylactic or other irreversible or life\u2010threatening side\u2010effects, and our study observed some long\u2010term responses. Further prospective investigation of anti\u2010EGFR antibodies, in association with anti\u2010PD\u20101 antibodies and\/or chemotherapy, should be conducted.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.16465","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T18:58:46Z","timestamp":1586977126000},"page":"2789-2794","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of panitumumab alone or in association with radiotherapy in unresectable cutaneous squamous cell carcinoma"],"prefix":"10.1111","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0662-8846","authenticated-orcid":false,"given":"K.","family":"Hourbeigt","sequence":"first","affiliation":[{"name":"Department of Oncodermatology Reims University Hospital Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ehret","sequence":"additional","affiliation":[{"name":"Department of Oncodermatology Reims University Hospital Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Visseaux","sequence":"additional","affiliation":[{"name":"Department of Oncodermatology Reims University Hospital Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3330-3505","authenticated-orcid":false,"given":"A.","family":"Durlach","sequence":"additional","affiliation":[{"name":"Department of Biopathology Reims University Hospital Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Petit","sequence":"additional","affiliation":[{"name":"Department of Oncodermatology Reims University Hospital Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Department of Oncodermatology Reims University Hospital Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Grange\u2010Prunier","sequence":"additional","affiliation":[{"name":"Department of Oncodermatology Reims University Hospital Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3683-5152","authenticated-orcid":false,"given":"C.","family":"Barbe","sequence":"additional","affiliation":[{"name":"Methodological Support Unit Reims University Hospital Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9760-3208","authenticated-orcid":false,"given":"S.","family":"Servagi\u2010Vernat","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Institut Jean Godinot Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3387-0283","authenticated-orcid":false,"given":"F.","family":"Grange","sequence":"additional","affiliation":[{"name":"Department of Oncodermatology Reims University Hospital Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,8,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103293441306"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802656"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71198-2"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.2.364"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.1735"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1754-9485.12842"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2018.09.257"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13741"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000461578"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.751481"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/284582"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e32809ef9e0"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2011.07.007"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000799"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu368"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.9534"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS9598"},{"key":"e_1_2_7_20_1","unstructured":"ECOG Performance Status [Internet].ECOG\u2010ACRIN.URLhttps:\/\/ecog\u2010acrin.org\/resources\/ecog\u2010performance\u2010status(last accessed: cited 7 November 2019)."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_7_23_1","unstructured":"Common Terminology.Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP [Internet]. URLhttps:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40(last accessed: 7 November 2019)."},{"key":"e_1_2_7_24_1","first-page":"1935","article-title":"Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck","volume":"59","author":"Huang S","year":"1999","journal-title":"Can Res"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053422"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70311-0"},{"key":"e_1_2_7_27_1","first-page":"1111","article-title":"Clinical study of cetuximab combined with radical radiotherapy in the treatment of locally advanced sinonasal squamous cell carcinoma","volume":"23","author":"Qiu X","year":"2018","journal-title":"J BUON"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.16465","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16465","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.16465","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T19:22:38Z","timestamp":1693423358000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.16465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,24]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1111\/jdv.16465"],"URL":"https:\/\/doi.org\/10.1111\/jdv.16465","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,24]]},"assertion":[{"value":"2019-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}